Literature DB >> 16161395

Success of mineral trioxide aggregate in pulpotomized primary molars.

Najat Farsi1, Najlaa Alamoudi, Khalid Balto, Abdullah Mushayt.   

Abstract

UNLABELLED: The aim of the present study was to compare, clinically and radiographically, the mineral trioxide aggregate (MTA) to formocresol (FC) when used as medicaments in pulpotomized vital human primary molars.
METHODS: The sample consisted of 120 primary molars, all teeth were treated with the same conventional pulpotomy technique. Sixty molars received FC and 60 received MTA throughout a random selection technique.
RESULTS: At the end of 24-month evaluation period, 74 molars (36 FC, 38 MTA) were available for clinical and radiographic evaluation. None of the MTA treated teeth showed any clinical or radiographic pathology, while the FC group showed a success rate of 86.8% radiographically and 98.6% clinically. The difference between the two groups in the radiographic outcomes was statistically significant. It was concluded that MTA treated molars demonstrated significantly greater success. MTA seems to be a suitable replacement for formocresol in pulpotomized primary teeth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16161395     DOI: 10.17796/jcpd.29.4.n80t77w625118k73

Source DB:  PubMed          Journal:  J Clin Pediatr Dent        ISSN: 1053-4628            Impact factor:   1.065


  37 in total

1.  Comparing gray mineral trioxide aggregate and diluted formocresol in pulpotomized human primary molars.

Authors:  Cameron M Zealand; Daniel M Briskie; Tatiana M Botero; James R Boynton; Jan C C Hu
Journal:  Pediatr Dent       Date:  2010 Sep-Oct       Impact factor: 1.874

2.  Short-term treatment outcome of pulpotomies in primary molars using mineral trioxide aggregate and Biodentine: a randomized clinical trial.

Authors:  C Cuadros-Fernández; A I Lorente Rodríguez; S Sáez-Martínez; J García-Binimelis; I About; M Mercadé
Journal:  Clin Oral Investig       Date:  2015-11-18       Impact factor: 3.573

Review 3.  Mineral trioxide aggregate versus formocresol pulpotomy: a systematic review and meta-analysis of randomized clinical trials.

Authors:  Armin Shirvani; Saeed Asgary
Journal:  Clin Oral Investig       Date:  2014-01-23       Impact factor: 3.573

4.  Prognostic factors for the survival of primary molars following pulpotomy with mineral trioxide aggregate: a retrospective cohort study.

Authors:  Chi Hoon Kim; Jee Soo Bae; Ik-Hwan Kim; Je Seon Song; Hyung-Jun Choi; Chung-Min Kang
Journal:  Clin Oral Investig       Date:  2020-08-04       Impact factor: 3.573

5.  In vivo evaluation of the treatment outcome of pulpotomy in primary molars using diode laser, formocresol, and ferric sulphate.

Authors:  Basak Durmus; Ilknur Tanboga
Journal:  Photomed Laser Surg       Date:  2014-04-09       Impact factor: 2.796

6.  Clinical Evaluation of Low Level Diode Laser Application For Primary Teeth Pulpotomy.

Authors:  K S Uloopi; C Vinay; A Ratnaditya; A Satya Gopal; K J N Mrudula; R Chandrasekhar Rao
Journal:  J Clin Diagn Res       Date:  2016-01-01

7.  Reparative dentinogenesis induced by mineral trioxide aggregate: a review from the biological and physicochemical points of view.

Authors:  Takashi Okiji; Kunihiko Yoshiba
Journal:  Int J Dent       Date:  2009-12-28

8.  Comparison of gray mineral trioxide aggregate and diluted formocresol in pulpotomized primary molars: a 6- to 24-month observation.

Authors:  John M Sushynski; Cameron M Zealand; Tatiana M Botero; James R Boynton; Robert F Majewski; Charles E Shelburne; Jan Chingchun Hu
Journal:  Pediatr Dent       Date:  2012 Sep-Oct       Impact factor: 1.874

Review 9.  Mineral trioxide aggregate as a pulpotomy medicament: an evidence-based assessment.

Authors:  F K Ng; L B Messer
Journal:  Eur Arch Paediatr Dent       Date:  2008-06

10.  A comparison of knowledge of local analgesia, pulp therapy and restoration of primary molar teeth amongst dental students, dentists and dental therapists within a dental hospital setting.

Authors:  J Foley
Journal:  Eur Arch Paediatr Dent       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.